 |
市場調査レポート
商品コード
941366
心房細動の世界市場：処置別および地域別市場分析、シェア、動向、規模、予測（2020年～2026年）Atrial Fibrillation Market, By Procedure (Pharmacological Drugs, Non-Pharmacological Treatment ) and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2020-2026 |
||||||
| 心房細動の世界市場：処置別および地域別市場分析、シェア、動向、規模、予測（2020年～2026年） |
|
出版日: 2020年05月01日
発行: AnalystView Market Insights
ページ情報: 英文 177 Pages
納期: 2-3営業日
|
世界の心房細動市場は、2019年までに143億8,000万米ドルと評価され、予測期間中の2020年から2026年の間にCAGR 14.9％で成長すると予測されています。
高齢者人口の増加に伴う心房細動の有病率の増加が、 世界の心房細動市場の成長を促進する主要な要因となっています。さらに、高血圧、僧帽弁狭窄症、肺塞栓症、甲状腺機能亢進症、肥満、肺炎などの疾患を引き起こす心房細動の発生率の増加は、この障害の有病率の増加の原因となる注目すべき要因の一つです。世界保健機関（WHO）によれば、世界中の75歳以上人口の約11％が心房細動に苦しんでいます。さらに、心臓の不整脈を治療するためのカテーテルアブレーション選好の増加と相まって、医療観光の増加が、業界成長をさらに促進します。逆に、心房細動に関する医薬品に対する否定的な印象、デバイスに関連する高コスト、および熟練した専門家の不足が、今後の市場の成長を阻害すると予想されています。それ以上に、低侵襲的処置と技術進歩に対するニーズの高まりにより、予測期間中に市場全体で有益な成長機会が生まれると予測されています。
当レポートでは、世界の心房細動市場について調査分析し、市場概要、市場動向、産業分析、市場情勢、セグメント別の市場分析、主要企業などについて、体系的な情報を提供しています。
Atrial fibrillation market was valued at USD 14.38 billion by 2019, growing with 14.9% CAGR during the forecast period, 2020-2026.
Atrial fibrillation is an irregular or rapid rhythm of the heart, which increases the risk of stroke, heart, blood clots, and other complications. In atrial fibrillation, the upper chambers of the heartbeats irregularly in a very rapid pattern, which results in slowing down of blood flow. The complications of atrial fibrillation include pressure, angina, or chest pain that leads to congestive heart failure. Fainting, fatigue, dizziness, and confusion are some of the symptoms of atrial fibrillation.
Market Dynamics
The growing prevalence of atrial fibrillation along with the increasing geriatric population is a major factor driving the growth of the global atrial fibrillation market. In addition, the growing incidence rates of atrial fibrillation causing diseases such as high blood pressure, mitral stenosis, pulmonary embolus, hyperthyroidism, obesity, and pneumonia is one of the notable factors responsible for the growing prevalence of this disorder. According to the World Health Organization (WHO), about 11% of the population aged 75 years and above all across the globe, suffer from atrial fibrillation. Furthermore, the rise in medical tourism coupled with the rising preference of catheter ablation for treating cardiac arrhythmia will propel the industry growth further. Conversely, the unfavorable inclination towards pharmaceutical drugs over atrial fibrillation, high costs associated with the devices, and lack of skilled professionals are expected to hamper the market growth in the coming future. On the contrary, the rising need for minimally invasive procedures and technological advancements are predicted to create lucrative growth opportunities in the overall market during the forecast period.
Procedure Takeaway
Based on the procedure, the worldwide market for atrial fibrillation is categorized into pharmacological drugs and non-pharmacological treatments. The pharmacological drugs segment includes anticoagulation and antiarrhythmic drugs. Further, the non-pharmacological treatment segment is sub-categorized into electric cardioversion, maze surgery, and the catheter ablation procedures into HIFU, radiofrequency, laser, microwave, and cryoablation. Among these, the catheter ablation surgical devices are the most commonly used for treating cardiac arrhythmias. These surgical devices are also used for the treatment of atrial fibrillation when anti-coagulant drugs and other medications are not tolerated or administered by the patient. Thus, the catheter ablation segment is estimated to dominate the market in terms of revenue in the forecast period. Moreover, an increase in the adoption rate of the catheter ablation system is expected to increase steadily, owing to the growing procedural success rate in patients that suffer from permanent, persistent, and paroxysmal conditions of atrial fibrillation.
Among the surgical catheter ablation, microwave and radiofrequency are the most commonly used catheter ablation procedures. The faster recovery rate of these procedures and the decreased size of the cardiac incision are other factors contributing to the segmental market growth.
REGIONAL TAKEAWAY
Regionally, the global industry is divided into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. The North America region accounted for the majority of share in 2019 and is estimated to dominate the industry during the forecast period. This dominance is majorly attributed to the growing adoption of technological advancements and the presence of sophisticated healthcare infrastructure. In addition, the governments of several countries and market players are investing more in atrial fibrillation procedures, which is anticipated to boost the regional market growth.
On the other hand, the Asia Pacific market for atrial fibrillation is anticipated to witness the fastest growth during the forecast period. This is mainly owing to the vast population and various age groups being vulnerable to cardiac diseases. Besides, the rising demand for atrial fibrillation devices and improving healthcare infrastructure are predicted to propel the growth of the Asia Pacific region.
COVID-19 Impact
The sudden outbreak of the COVID-19 pandemic has immensely affected the global atrial fibrillation market. The key players of the industry have built and broken various value-grab opportunities to sustain in these trying times. They are capitalizing on novel strategies to obtain and maintain a stable revenue income. However, the global market is estimated to recover soon after the coronavirus chaos.
KEY VENDOR TAKEAWAY
The leading players of the global atrial fibrillation market include Sanofi-Aventis, AtriCure Inc., Biosense Webster Inc., CardioFocus Inc., Bristol-Myers Squibb Corporation, Boston Scientific Corporation, Endoscopic Technologies Inc., Johnson & Johnson Ltd., St. Jude Medical Inc., and Boehringer Ingelheim GmbH. These players are implementing various strategies such as mergers, acquisitions, and technological advancements to hold a strong position in the global industry.
For instance, in August 2019, a leading innovator in treatments for left atrial appendage (LAA) and atrial fibrillation, AtriCure, Inc. acquired SentreHEART by entering into an agreement. The company's aim behind this acquisition is to provide better atrial fibrillation treatment and expand their business.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2015 to2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2026
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
Scope of the Report
The scope of this report covers the market by its major segments, which include as follows:
KEY PLAYERS
Sanofi-Aventis
AtriCure Inc.
Biosense Webster Inc.
CardioFocus Inc.
Bristol-Myers Squibb Corporation
Boston Scientific Corporation
Endoscopic Technologies Inc.
Johnson & Johnson Ltd.
Jude Medical Inc.
Boehringer Ingelheim GmbH
ATRIAL FIBRILLATION MARKET, BY PROCEDURE
Pharmacological Drugs
Anti-arrhythmic Drugs
Anticoagulant Drugs
Non-Pharmacological Treatment
Catheter Ablation Procedures
HIFU
Radiofrequency
Laser
Microwave
Cryoablation
Maze Surgery
Electric Cardioversion
ATRIAL FIBRILLATION MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA
比較リスト
